Bicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment

MT Newswires Live

Dec 08, 2025

Bicara Therapeutics (BCAX) said Saturday that preliminary data from a phase 1b study cohort evaluating a 750 milligram dose of its drug ficerafusp alfa weekly in combination with pembrolizumab was well-tolerated as a first-line treatment for human papillomavirus-negative recurrent/metastatic head and neck squamous cell carcinoma.

The company said the dose showed a 57% overall response rate, with 10% achieving a completed response, and 29% of responsive patients showing at least 80% tumor shrinkage.

The company said data from the study advanced its dose-optimization strategy, putting it on track to declare an optimal dose in Q1.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2589337903"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589337903\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589337903?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 19:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589337903","market":"hk","top_or_hot":-1,"title":"Bicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/BCAX\">Bicara Therapeutics</a> (BCAX) said Saturday that preliminary data from a phase 1b study cohort evaluating a 750 milligram dose of its drug ficerafusp alfa weekly in combination with pembrolizumab was well-tolerated as a first-line treatment for human papillomavirus-negative recurrent/metastatic head and neck squamous cell carcinoma.</p><p>The company said the dose showed a 57% overall response rate, with 10% achieving a completed response, and 29% of responsive patients showing at least 80% tumor shrinkage.</p><p>The company said data from the study advanced its dose-optimization strategy, putting it on track to declare an optimal dose in Q1.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-08 19:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/BCAX\">Bicara Therapeutics</a> (BCAX) said Saturday that preliminary data from a phase 1b study cohort evaluating a 750 milligram dose of its drug ficerafusp alfa weekly in combination with pembrolizumab was well-tolerated as a first-line treatment for human papillomavirus-negative recurrent/metastatic head and neck squamous cell carcinoma.</p><p>The company said the dose showed a 57% overall response rate, with 10% achieving a completed response, and 29% of responsive patients showing at least 80% tumor shrinkage.</p><p>The company said data from the study advanced its dose-optimization strategy, putting it on track to declare an optimal dose in Q1.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCAX","symbol_name":"Bicara Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2589337903","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589337903","pubTimestamp":1765195027,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bicara Therapeutics (BCAX) said Saturday that preliminary data from a phase 1b study cohort evaluating a 750 milligram dose of its drug ficerafusp alfa weekly in combination with pembrolizumab was wel","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCAX":"Bicara Therapeutics","BK4139":"生物科技"},"translate_title":"Bicara Therapeutics推进潜在颈、头癌治疗的剂量优化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCAX":1.5},"content_text":"Bicara Therapeutics (BCAX) said Saturday that preliminary data from a phase 1b study cohort evaluating a 750 milligram dose of its drug ficerafusp alfa weekly in combination with pembrolizumab was well-tolerated as a first-line treatment for human papillomavirus-negative recurrent/metastatic head and neck squamous cell carcinoma.The company said the dose showed a 57% overall response rate, with 10% achieving a completed response, and 29% of responsive patients showing at least 80% tumor shrinkage.The company said data from the study advanced its dose-optimization strategy, putting it on track to declare an optimal dose in Q1.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}